Thioaptamer Interactions with Prion Proteins: Sequence-specific and Non-specific Binding Sites

Journal of Molecular Biology

Volumn 369, Issue 4, 2007, Pages 1001-1014

  King, David J ^a   Safar, Jiri G ^a,b   Legname, Giuseppe ^a,b   Prusiner, Stanley B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

aptamer; phosphorothioate; prions; thioaptamer

Indexed keywords

APTAMER; OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID DERIVATIVE; PRION PROTEIN; SINGLE STRANDED DNA; THIOAPTAMER; UNCLASSIFIED DRUG;

ALPHA HELIX; AMINO ACID SEQUENCE; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONFORMATION; CONSENSUS SEQUENCE; DNA BINDING; DNA LIBRARY; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN STRUCTURE; SYRIAN HAMSTER;

BOVINAE; MESOCRICETUS AURATUS;

EID: 34248598028     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2007.02.004     Document Type: Article

References (63)

1. Sigurdsson B. Rida, a chronic encephalitis of sheep with general remarks on infections which develop slowly and some of their special characteristics. Br. Vet. J. 110 (1954) 341-354
2. Gibbs Jr. C.J., Gajdusek D.C., Asher D.M., Alpers M.P., Beck E., Daniel P.M., and Matthews W.B. Creutzfeldt-Jakob disease (spongiform encephalopathy): transmission to the chimpanzee. Science 161 (1968) 388-389
3. Pattison I.H., and Millson G.C. Scrapie produced experimentally in goats with special reference to the clinical syndrome. J. Comp. Pathol. 71 (1961) 101-108
4. Dickinson A.G., and Meikle V.M. A comparison of some biological characteristics of the mouse-passaged scrapie agents, 22A and ME7. Genet. Res. 13 (1969) 213-225
5. Alper T., Cramp W.A., Haig D.A., and Clarke M.C. Does the agent of scrapie replicate without nucleic acid?. Nature 214 (1967) 764-766
6. Gibbs Jr. C.J., Gajdusek D.C., and Latarjet R. Unusual resistance to ionizing radiation of the viruses of kuru, Creutzfeldt-Jakob disease. Proc. Natl Acad. Sci. USA 75 (1978) 6268-6270
7. Prusiner S.B. Novel proteinaceous infectious particles cause scrapie. Science 216 (1982) 136-144
8. Meyer N., Rosenbaum V., Schmidt B., Gilles K., Mirenda C., Groth D., et al. Search for a putative scrapie genome in purified prion fractions reveals a paucity of nucleic acids. J. Gen. Virol. 72 (1991) 37-49
9. Kellings K., Meyer N., Mirenda C., Prusiner S.B., and Riesner D. Further analysis of nucleic acids in purified scrapie prion preparations by improved return refocussing gel electrophoresis (RRGE). J. Gen. Virol. 73 (1992) 1025-1029
10. Safar J.G., Kellings K., Serban A., Groth D., Cleaver J.E., Prusiner S.B., and Riesner D. Search for a prion-specific nucleic acid. J. Virol. 79 (2005) 10796-10806
11. Cordeiro Y., Machado F., Juliano L., Juliano M.A., Brentani R.R., Foguel D., and Silva J.L. DNA converts cellular prion protein into the beta-sheet conformation and inhibits prion peptide aggregation. J. Biol. Chem. 276 (2001) 49400-49409
12. Gabus C., Derrington E., Leblanc P., Chnaiderman J., Dormont D., Swietnicki W., et al. The prion protein has RNA binding and chaperoning properties characteristic of nucleocapsid protein NCP7 of HIV-1. J. Biol. Chem. 276 (2001) 19301-19309
13. Gabus C., Auxilien S., Pechoux C., Dormont D., Swietnicki W., Morillas M., et al. The prion protein has DNA strand transfer properties similar to retroviral nucleocapsid protein. J. Mol. Biol. 307 (2001) 1011-1021
14. Nandi P.K., and Sizaret P.Y. Murine recombinant prion protein induces ordered aggregation of linear nucleic acids to condensed globular structures. Arch. Virol. 146 (2001) 327-345
15. Nandi P.K., Leclerc E., Nicole J.C., and Takahashi M. DNA-induced partial unfolding of prion protein leads to its polymerisation to amyloid. J. Mol. Biol. 322 (2002) 153-161
16. Deleault N.R., Lucassen R.W., and Supattapone S. RNA molecules stimulate prion protein conversion. Nature 425 (2003) 717-720
17. Deleault N.R., Geoghegan J.C., Nishina K., Kascsak R., Williamson R.A., and Supattapone S. Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions. J. Biol. Chem. 280 (2005) 26873-26879
18. Bessen R.A., and Marsh R.F. Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. J. Virol. 68 (1994) 7859-7868
19. Telling G.C., Parchi P., DeArmond S.J., Cortelli P., Montagna P., Gabizon R., et al. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 274 (1996) 2079-2082
20. Peretz D., Williamson R.A., Legname G., Matsunaga Y., Vergara J., Burton D., et al. A change in the conformation of prions accompanies the emergence of a new prion strain. Neuron 34 (2002) 921-932
21. Legname G., Nguyen H.-O.B., Baskakov I.V., Cohen F.E., DeArmond S.J., and Prusiner S.B. Strain-specified characteristics of mouse synthetic prions. Proc. Natl Acad. Sci. USA 102 (2005) 2168-2173
22. Tanaka M., Collins S.R., Toyama B.H., and Weissman J.S. The physical basis of how prion conformations determine strain phenotypes. Nature 442 (2006) 585-589
23. Ye X., Gorin A., Ellington A.D., and Patel D.J. Deep penetration of an alpha-helix into a widened RNA major groove in the HIV-1 rev peptide-RNA aptamer complex. Nature Struct. Biol. 3 (1996) 1026-1033
24. Mao X., Marky L.A., and Gmeiner W.H. NMR structure of the thrombin-binding DNA aptamer stabilized by Sr2+. J. Biomol. Struct. Dynam. 22 (2004) 25-33
25. Weiss S., Proske D., Neumann M., Groschup M.H., Kretzschmar H.A., Famulok M., and Winnacker E.L. RNA aptamers specifically interact with the prion protein PrP. J. Virol. 71 (1997) 8790-8797
26. Sc formation. Chembiochem. 3 (2002) 717-725
27. Takemura K., Wang P., Vorberg I., Surewicz W., Priola S.A., Kanthasamy A., et al. DNA aptamers that bind to PrP(C) and not PrP(Sc) show sequence and structure specificity. Exp. Biol. Med. 231 (2006) 204-214
28. Rhie A., Kirby L., Sayer N., Wellesley R., Disterer P., Sylvester I., et al. Characterization of 2′-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion. J. Biol. Chem. 278 (2003) 39697-39705
29. Sayer N.M., Cubin M., Rhie A., Bullock M., Tahiri-Alaoui A., and James W. Structural determinants of conformationally selective, prion-binding aptamers. J. Biol. Chem. 279 (2004) 13102-13109
30. Eckstein F. Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them?. Antisense Nucl. Acid Drug Dev. 10 (2000) 117-121
31. Marshall W.S., Beaton G., Stein C.A., Matsukura M., and Caruthers M.H. Inhibition of human immunodeficiency virus activity by phosphorodithioate oligodeoxycytidine. Proc. Natl Acad. Sci. USA 89 (1992) 6265-6269
32. Garcia G.A., Leatherbarrow R.J., Eckstein F., and Fersht A.R. Metal ion dependence of phosphorothioate ATP analogues in the Bacillus stearothermophilus tyrosyl-tRNA synthetase reaction. Biochemistry 29 (1990) 1643-1648
33. King D.J., Bassett S.E., Li X., Fennewald S.A., Herzog N.K., Luxon B.A., et al. Combinatorial selection and binding of phosphorothioate aptamers targeting human NF-kappa B RelA(p65) and p50. Biochemistry 41 (2002) 9696-9706
34. Sethi S., Lipford G., Wagner H., and Kretzschmar H. Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet 360 (2002) 229-230
35. Kocisko D.A., Vaillant A., Lee K.S., Arnold K.M., Bertholet N., Race R.E., et al. Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. Antimicrob. Agents Chemother. 50 (2006) 1034-1044
36. Bailey T.L., and Gribskov M. Methods and statistics for combining motif match scores. J. Comput. Biol. 5 (1998) 211-221
37. Bailey T.L., and Gribskov M. Score distributions for simultaneous matching to multiple motifs. J. Comput. Biol. 4 (1997) 45-59
38. Bailey T.L., and Elkan C. The value of prior knowledge in discovering motifs with MEME. Proc. Int. Conf. Intell. Syst. Mol. Biol. 3 (1995) 21-29
39. Pan K.-M., Stahl N., and Prusiner S.B. Purification and properties of the cellular prion protein from Syrian hamster brain. Protein Sci. 1 (1992) 1343-1352
40. van Holde K.E. Physical Biochemistry. 2nd edit. (1985), Prentice Hall, Upper Saddle River
41. Zahn R., Liu A., Lührs T., Riek R., von Schroetter C., López García F., et al. NMR solution structure of the human prion protein. Proc. Natl Acad. Sci. USA 97 (2000) 145-150
42. López García F., Zahn R., Riek R., and Wüthrich K. NMR structure of the bovine prion protein. Proc. Natl Acad. Sci. USA 97 (2000) 8334-8339
43. Kowalczykowski S.C., Lonberg N., Newport J.W., Paul L.S., and von Hippel P.H. On the thermodynamics and kinetics of the cooperative binding of bacteriophage T4-coded gene 32 (helix destabilizing) protein to nucleic acid lattices. Biophys. J. 32 (1980) 403-418
44. Mercey, R. Lantier I., Maurel M.C., Grosclaude J., Lantier F. & Marc, D. (2006). Fast, reversible interaction of prion protein with RNA aptamers containing specific sequence patterns. Arch. Virol. 151, 2197-2214.
45. Nandi P.K. Polymerization of human prion peptide HuPrP 106-126 to amyloid in nucleic acid solution. Arch. Virol. 143 (1998) 1251-1263
46. Lima L.M., Cordeiro Y., Tinoco L.W., Marques A.F., Oliveira C.L., Sampath S., et al. Structural insights into the interaction between prion protein and nucleic acid. Biochemistry 45 (2006) 9180-9187
47. Govaerts C., Wille H., Prusiner S.B., and Cohen F.E. Evidence for assembly of prions with left-handed β-helices into trimers. Proc. Natl Acad. Sci. USA 101 (2004) 8342-8347
48. Marshall W.S., and Caruthers M.H. Phosphorodithioate DNA as a potential therapeutic drug. Science 259 (1993) 1564-1570
49. DeLong R.K., Nolting A., Fisher M., Chen Q., Wickstrom E., Kligshteyn M., et al. Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice. Antisense Nucl. Acid Drug Dev. 7 (1997) 71-77
50. Sc)-specific epitope defined by a monoclonal antibody. Nature 389 (1997) 74-77
51. Paramithiotis E., Pinard M., Lawton T., LaBoissiere S., Leathers V.L., Zou W.Q., et al. A prion protein epitope selective for the pathologically misfolded conformation. Nature Med. 9 (2003) 893-899
52. Supattapone S., Wille H., Uyechi L., Safar J., Tremblay P., Szoka F.C., et al. Branched polyamines cure prion-infected neuroblastoma cells. J. Virol. 75 (2001) 3453-3461
53. Daude N., Marella M., and Chabry J. Specific inhibition of pathological prion protein accumulation by small interfering RNAs. J. Cell Sci. 116 (2003) 2775-2779
54. Tatzelt J., Prusiner S.B., and Welch W.J. Chemical chaperones interfere with the formation of scrapie prion protein. EMBO J. 15 (1996) 6363-6373
55. Mehlhorn I., Groth D., Stöckel J., Moffat B., Reilly D., Yansura D., et al. High-level expression and characterization of a purified 142-residue polypeptide of the prion protein. Biochemistry 35 (1996) 5528-5537
56. Baskakov I.V., Legname G., Prusiner S.B., and Cohen F.E. Folding of prion protein to its native α-helical conformation is under kinetic control. J. Biol. Chem. 276 (2001) 19687-19690
57. C on the cell surface as probed by antibodies. J. Mol. Biol. 326 (2003) 475-483
58. Peretz D., Williamson R.A., Kaneko K., Vergara J., Leclerc E., Schmitt-Ulms G., et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412 (2001) 739-743
59. Safar J.G., Scott M., Monaghan J., Deering C., Didorenko S., Vergara J., et al. Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nature Biotechnol. 20 (2002) 1147-1150
60. Jezewska M.J., Lucius A.L., and Bujalowski W. Binding of six nucleotide cofactors to the hexameric helicase RepA protein of plasmid RSF1010. 2. Base specificity, nucleotide structure, magnesium, and salt effect on the cooperative binding of the cofactors. Biochemistry 44 (2005) 3877-3890
61. Jezewska M.J., Lucius A.L., and Bujalowski W. Binding of six nucleotide cofactors to the hexameric helicase RepA protein of plasmid RSF1010. 1. Direct evidence of cooperative interactions between the nucleotide-binding sites of a hexameric helicase. Biochemistry 44 (2005) 3865-3876
62. Indyk L., and Fisher H.F. Theoretical aspects of isothermal titration calorimetry. Methods Enzymol. 295 (1998) 350-364
63. Eftink M.R. Fluorescence methods for studying equilibrium macromolecule-ligand interactions. Methods Enzymol. 278 (1997) 221-257